Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013

Diomandé, Fabien; Yaméogo, Tènè Marceline; Vannice, Kirsten; Préziosi, Marie-Pierre; Viviani, Simonetta; Ouandaogo, Claude-Roger; Keita, Modibo; Djingarey, Mamoudou Harouna; Mbakuliyemo, Nehemie; Akanmori, Bartholomew D.; Sow, Samba O.; Zuber, Patrick L. F.

doi:10.1093/cid/civ599

Cited by 15 publications

(11 citation statements)

References 14 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 However, the introduction of new vaccination cards in some circumstances has been met with confusion on the part of health-care providers. 12 In a situation where bureaucracy or lack of training prevents the change of these cards, it might be more beneficial to design a coverslip instead which would convey some minimal but important information to parents: where to get vaccinated, when to show up next, and maybe a simplified diagram of what diseases their child is protected against. This coverslip could also enhance the durability of the vaccination card but would not require additional training for vaccination providers.…”

Section: Recommendations For Usementioning

confidence: 99%

The use and significance of vaccination cards

Wagner

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vaccination cards are useful health records that contain information about vaccination dates and dosage. This information is helpful for parents, vaccination providers, and public health researchers. However, as they currently are structured, many vaccination cards are very difficult to read by non-experts, like parents, and even by health-care providers. Many families also lose these vaccination cards; among the top 10 countries with the most unvaccinated children, the proportion of families who were able to find their vaccination cards and give them to researchers was low, ranging from 20.7% in the Democratic Republic of the Congo to 69.2% in South Africa. Moreover, some families report that not having a vaccination card during a vaccination visit resulted in them being unable to obtain a vaccine (8% in one study in Ethiopia and 16% in one study in Bangladesh). This commentary provides recommendations about how vaccination cards should be used by parents, health-care providers, and researchers, and comments on their continued relevance in an era with increased use of electronic registries.

show abstract

Section: Recommendations For Usementioning

confidence: 99%

The use and significance of vaccination cards

Wagner

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Additionally, a MenAfriNet project was introduced in 2015 to strengthen case-based surveillance in 4 countries (Mali, Niger Burkina Faso, and Togo). The vaccine has proved to be safe and effective, nd has significantly reduced the incidence and mortality due to group A meningococcal disease between 2010 and 2015 [8][9][10][11][12] . Meningitis cases and deaths have remained significantly lower than the peak in 2009 (Figure 2), while the proportion of meningitis cases caused by group A meningococci has declined steadily since 2010 (Figure 3).…”

Section: Meningitis Surveillancementioning

confidence: 99%

Elimination of Epidemic Meningitis in the African Region: Progress and Challenges:2010-2016

Fall¹,

Bita²,

Lingani³

et al. 2018

J Immunological Sci

Self Cite

View full text Add to dashboard Cite

Background Epidemics of meningococcal disease constitute a major public health challenge in Africa, affecting mostly the 24 countries of the meningitis belt. These epidemics led to a call for a call for a safe, effective and affordable conjugate vaccine against the major serogroup responsible for recent epidemics by leaders of the region. Objective This paper documents experiences with efforts at eliminating epidemic meningitis in the African Region. Method The meningoccocal serogroup A conjugate vaccine was developed, licensed and offered to more than 235 million people through mass vaccination campaigns in 16 countries since 2010. Future plans include providing the vaccine to the remaining countries in the African Meningitis Belt and, to implement the vaccine into routine national infant immunization programme and to organise catch-up immunization campaigns every 5 years for unvaccinated <5 year-olds who had missed their routine vaccinations. Results The success of the project is evidenced by the large declines in cases of group A meningococcal disease since 2010, with no cases reported in vaccinated persons across the 16 countries, reflecting the highly effective nature of the vaccine. The successful control of serogroup A meningococcal disease has highlighted the need to tackle other meningococcal serogroups through development of polyvalent conjugate vaccines with the aim of eliminating epidemics of meningococcal meningitis in the African region.

show abstract

“…Diomande's article on pharmacovigilance is particularly important given the all-too-common assertion that pharmacovigilance cannot be done in sub-Saharan Africa [ 2 ]. Similarly, the article by Wak et al clearly documents the safety of PsA-TT when given to pregnant women [ 3 ].…”

mentioning

confidence: 99%